Siemens Healthineers : Präsentation 'New levels of productivity and digitalization for the clinical lab' (English) ()

New levels of productivity and digitalization for the clinical lab

Diagnostics

Deepak Nath

President Laboratory Diagnostics

1

Unrestricted © Siemens Healthineers, 2020

Safe Harbour Statement

This presentation has been prepared solely for use at this meeting. This material is given in conjunction with an oral presentation and should not be taken out of context. By attending the meeting where this presentation

is held or accessing this presentation, you agree to be bound by the following limitations.

This presentation has been prepared for information purposes only and the information contained herein (unless otherwise indicated) has been provided by Siemens Healthineers AG. It does not constitute or form part of, and should not be construed as, an offer of, a solicitation of an offer to buy, or an invitation to subscribe for, underwrite or otherwise acquire, any securities of Siemens Healthineers AG or any existing or future member of the Siemens Healthineers Group (the "Group") or Siemens AG, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of Siemens Healthineers AG, any member of the Group or Siemens AG or with any other contract or commitment whatsoever. This presentation does not constitute a prospectus in whole or in part, and any decision to invest in

securities should be made solely on the basis of the information to be contained in a prospectus and on an independent analysis of the information contained therein.

Any assumptions, views or opinions (including statements, projections, forecasts or other forward-looking statements) contained in this presentation represent the assumptions, views or opinions of Siemens Healthineers AG, unless otherwise indicated, as of the date indicated and are subject to change without notice.

Siemens Healthineers neither intends, nor assumes any obligation, unless required by law, to update or revise these assumptions, views or opinions in light of developments which differ from those anticipated.

All information not separately sourced is from internal company data and estimates. Any data relating to past performance contained herein is no indication as to future performance. The information in this presentation is

not intended to predict actual results, and no assurances are given with respect thereto.

The information contained in this presentation has not been independently verified, and no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information contained herein and no reliance should be placed on it. None of Siemens Healthineers AG or any of its affiliates, advisers, affiliated persons or any other person accept any liability for any loss howsoever arising (in negligence or otherwise), directly or indirectly, from this presentation or its contents or otherwise arising in connection with this presentation. This shall not, however, restrict or exclude or limit any duty or liability to a person under any applicable law or regulation of any jurisdiction which may not lawfully be disclaimed (including in relation to fraudulent misrepresentation).

This document contains statements related to our future business and financial performance and future events or developments involving Siemens Healthineers that may constitute forward-looking statements. These

statements may be identified by words such as "expect", "forecast", "anticipate", "intend", "plan", "believe", "seek", "estimate", "will", "target" or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Siemens Healthineers' management, of which many are beyond Siemens Healthineers' control. As they relate to future events or developments, these statements are subject to a number of risks, uncertainties and factors, including, but not limited to those described in the respective disclosures. Should one or more of these risks, uncertainties or factors materialize, or should

underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Siemens Healthineers may (negatively or positively) vary materially from those described explicitly or

implicitly in the relevant forward-looking statement.

This document includes - in the applicable financial reporting framework not clearly defined - supplemental financial measures (financial key performance indicators) that are or may be alternative performance measures (non-GAAP measures). These supplemental financial measures may have limitations as analytical tools and should not be viewed in isolation or as alternatives to measures of Siemens Healthineers' net assets and financial positions or results of operations as presented in accordance with the applicable financial reporting framework in its half-year consolidated financial statements and consolidated financial statements. Other companies that report or describe similarly titled alternative performance measures may calculate them differently, which may therefore not be comparable.

Please find further explanations regarding our financial key performance indicators in chapter "A.2 Financial performance system" and in the notes to the consolidated financial statements note 29 "Segment information" in the Annual Report 2019 of Siemens Healthineers. Additional information is also included in the Quarterly Statement. These documents can be found under the following internet linkhttps://www.corporate.siemens-healthineers.com/investor-relations/presentations-financial-publications. As of beginning of fiscal year 2020, Siemens Healthineers applies the accounting standard IFRS 16, Leases. Comparative figures for the preceding fiscal year were not adjusted. Instead, the overall insignificant transition effects were recognized in equity as of October 1, 2019.

Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer.

Due to technical reasons, there may be discrepancies in formatting of the accounting data included in this document and made publicly available according to applicable legal rules. The information contained in this presentation is provided as of the date of this presentation and is subject to change without notice.

2

Unrestricted © Siemens Healthineers, 2020

Diagnostics - Building from a leading position with the broadest portfolio in the industry

Strong positions …… in an attractive market …… with global scale

				€28bn+	>5%		300k+	135+
Laboratory Automation Point-of-	Market	Market		Global Installed	Number of
Diagnostics	Care	Size1	CAGR1		Base2	Countries2
Decentralized settings						Centralized settings

Connected point-of-care solutions

Workflow excellence

Clinical

excellence

Automated, high throughput solutions

Urinalysis	Blood Gas	Digitalization	Atellica Solution (CC/IA)	Automation/IT

End-to-End Solutions

HbA1C	Cardiac	Informatics	Hematology	Coagulation	Urinalysis
					3
1 2019 BBC Annual IVD Market Book in USD and calendar year, excludes Molecular Diagnostics 2 Internal data		Unrestricted © Siemens Healthineers, 2020

Atellica® Solution delivers tangible value to customers

(catalyst for growth)

Customized configurations

33%

to meet individual lab needs

fewer analyzers 4

>35%

Seamless

integration of

Competitive wins

emergency and

routine testing

86%

>80%

fewer operators4

Advanced automated workflow

Remote proactive

Mega Lab2 competitive

73%

Highest immunoassay

monitoring and support

win rate with TLA3

to reduce manual interventions

productivity 1

less hands-on time 4

Designed to meet evolving

needs of customers…

+

…with good uptake

in the market…

=

…and tangible

customer impact.

Product availability may vary from country to country and is subject to varying regulatory requirements

1) Based on tests per hour per m2 when compared to leading competitive modular immunoassay instrument 2) Labs processing in excess of ~30 k tubes/day

3) TLA = Total Lab Automation 4) The outcomes obtained by individual Siemens Healthineers customers were realized in the customers unique setting. Since there is no typical laboratory, and many variables exist, there can be no guarantee that others will achieve the same results Source: Laboratory Diagnostics

4

Unrestricted © Siemens Healthineers, 2020

COVID-19 impacted performance - improvement expected in FY21

Grow Expand Elevate

Delivering on the promise of Atellica Solution

						Development of adjusted EBIT
						margin (illustrative)
FY19	Volume	COVID-19	Atellica	Other	FY20	FY21

Performance in FY20 significantly impacted by COVID

• Severe decline in routine care testing, partial recovery in Q4
• Continued "investment" in service and maturing Atellica systems: foundational to margin improvement in FY21, high seeding rates for Atellica instruments

Outlook FY21: improvement expected in both top and bottom line

• Routine care recovers but remains below 2019 levels
• Good progress in maturing of Atellica platform
• Improved factory utilization
• Strengthened leadership team

5

Unrestricted © Siemens Healthineers, 2020

Our portfolio innovations will deliver the lab of the future

Grow Expand Elevate

Workflow excellence

Clinical

excellence

Lead in workflow and achieve clinical excellence

Positioning ourselves for the future	Innovating in workflow
•	Deliver further Atellica innovations incl. Mid-Volume system (CI19001)	• Enhance and expand Atellica Solution IT
•	Launch assays to continue menu enrichment	• Strengthen laboratory automation offerings

1 In development. Future availability cannot be guaranteed.

6

Unrestricted © Siemens Healthineers, 2020

Best-in-class testing for COVID-19

Total Antibody Assay: IgG/IgM**

Both tests are CE-marked and

FDA EUA-authorized and run on

•

100% sensitivity, 99.8% specificity3

one of largest installed base of

CoV-SARS

have I Do

critical care tests for COVID-19

•

Utilizes the spike protein to detect total

high-throughput automated

antibodies to block the virus entry into human cells

analyzers worldwide

patients including

25 D-Dimer,IL-6*, SAA*, CRP,

IgG Quantitative Antibody Assay**

19?-COVID

Procalcitonin (PCT), TnIH

•

100% sensitivity, 99.9% specificity, 3

•

Measures levels of IgG neutralizing antibodies

virus?2-

thetoantibodies

to the spike protein, enabling tracking of

changes over time

Molecular SARS-CoV-2 test kit**

• FDA EUA-authorized,CE-marked, WHO EUL

• 100% positive, 100% negative agreements1

have

Rapid SARS-CoV-2 POC Antigen Test2

• CE-marked; under FDA review for EUA

Do I

• Portable visual read, 15-min. TAT

*Not available for sale in the U.S.

**These SARS-CoV-2 molecular and serology tests have not been FDA cleared or approved. These tests have been authorized by FDA under an EUA for use by authorized laboratories. The molecular test has been authorized only

5

for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The serology test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or

pathogens. These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under

Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Product availability may vary from country to country and is subject to varying regulatory requirements.

1) In method comparison studies, FTD SARS-CoV-2 has shown Positive Percent Agreement: 100% (91.8-100, 95% CI) and Negative Percent Agreement: 100% (88.7-100, 95% CI) when tested in Copan eSwab nasopharyngeal and
oropharyngeal swabs.
2) CE-IVD labeled for diagnostic use in the EU. Research Use Only (RUO) in the U.S.	7
3) For samples collected ≥14 days after positive PCR result.
5) www.thelancet.com Published online September 25, 2020 https://doi.org/10.1016/S0140-6736(20)32006-7 and Clarke C, Prendecki M, Dhutia A, et al. High prevalence of asymptomaticCOVID-19 infection in hemodialysis	Unrestricted © Siemens Healthineers, 2020
patients detected using serologic screening. J Am Soc Nephrol 2020; 31: 1969-75. Commentary from Barnaby Flower, Christina Atchison Department of Infectious Disease, Faculty of Medicine, Imperial College London